The clinical picture that emerged was stark and, in the most heavily exposed patient, relentless. After ingesting the soup, the affected individuals developed classic anticholinergic toxicity, the syndrome produced when plant-derived alkaloids block muscarinic acetylcholine receptors throughout the nervous system. The patient with the greatest exposure spiraled into metabolic acidosis and hyperlactatemia, followed by multiple organ failure, and could not be saved despite intensive emergency care. A second, less heavily exposed household member recovered fully after treatment, an outcome that underlines one of the most clinically important lessons of the incident: in tropane alkaloid poisoning, the dose received, and therefore the amount of contaminated plant consumed, can determine the difference between a survivable intoxication and a fatal one. The investigators emphasize that this kind of dose-dependent outcome, seen within a single family eating the same meal, illustrates the steep toxicity curve of Datura alkaloids.

Identifying the plant behind the poisoning required two independent lines of evidence. The team first examined the suspected seedlings morphologically, comparing their physical characteristics with botanical descriptions of Datura stramonium. They then confirmed the identification using sequence-based molecular analysis, a DNA barcoding approach that removes the ambiguity that sometimes accompanies visual identification of young plants. Seedlings of jimson weed can resemble edible wild greens closely enough to fool foragers, and this resemblance is precisely why the plant is such a persistent hazard in rural communities where wild vegetable collection remains common. The dual identification strategy, combining classical botany with molecular confirmation, is presented by the authors as a model for source attribution in poisoning investigations, providing a defensible link between the plant on the table and the symptoms in the patients.

The quantitative core of the study is arguably its most striking contribution. Using ultra-performance liquid chromatography coupled with tandem mass spectrometry, the researchers measured the concentrations of three major tropane alkaloids, atropine, scopolamine and anisodamine, in different parts of the single plant specimen recovered from the incident. The results revealed dramatic variation across plant structures. Atropine reached its highest concentrations in immature fruits, at approximately 280 milligrams per kilogram, and in flowers, at approximately 160 milligrams per kilogram. Scopolamine peaked in mature fruits at roughly 80 milligrams per kilogram and in flowers at about 60 milligrams per kilogram. Anisodamine was present at lower levels overall, with its maximum in flowers at approximately 19.25 milligrams per kilogram. These figures demonstrate that alkaloid distribution is not uniform within a single plant, and that even seedling material from the same plant can carry very different toxicological burdens.

The analytical method itself was validated to standards suitable for forensic and regulatory work. The UPLC-MS/MS assay exhibited good linearity across its calibration range, with correlation coefficients of at least 0.9982, recoveries ranging from 84.90 percent to 100.9 percent, and relative standard deviations below 7.7 percent. This level of precision matters because the concentrations being measured determine how a poisoning event is interpreted. A laboratory result with poor reproducibility could not reliably support source attribution, whereas the validated performance reported here allows the measured alkaloid levels to be taken as credible evidence that the plant consumed carried potentially lethal quantities of anticholinergic toxins. The assay now stands as a technical reference for any laboratory faced with a suspected Datura poisoning and a plant sample to analyze.

Beyond the incident reconstruction, the researchers ventured into exploratory computational territory, using network toxicology and molecular docking to explore the molecular machinery that tropane alkaloids might disturb in the nervous system. By integrating databases of toxin targets and neurotoxicity-related genes, the team identified 360 overlapping targets associated with the neurotoxic effects of atropine, scopolamine and anisodamine. Enrichment analyses pointed toward oxidative stress processes and kinase-related biological functions, as well as signaling pathways including PI3K-Akt and ErbB. These pathways are central to cell survival, growth and signaling cascades in neurons, and their appearance in the analysis suggests that the neurotoxicity of tropane alkaloids may not be limited to the well-characterized blockade of muscarinic receptors but could involve secondary molecular responses triggered downstream of receptor inhibition.

Molecular docking, a computational technique that predicts how small molecules fit into the binding pockets of proteins, added another layer to this hypothesis-generating exercise. The docking experiments suggested theoretical binding compatibility between all three alkaloids and several of the predicted core targets, with the strongest predicted interactions involving AKT1 and PIK3CA, two key components of the PI3K-Akt signaling axis. The authors are careful to frame these findings appropriately: computational predictions of binding do not demonstrate biological effect, and the entire computational component is presented as exploratory rather than conclusive. Nevertheless, by nominating specific kinases and pathways for future laboratory validation, the analysis provides a roadmap for experimental work that could clarify whether antioxidant strategies or pathway-targeted interventions might eventually complement the supportive care that currently defines anticholinergic poisoning treatment.

The investigators are equally candid about the limitations of their source attribution. Because no toxicological measurements were carried out in the patients’ biological specimens, the study cannot confirm internal exposure to the alkaloids directly. The chain of evidence is therefore epidemiological and botanical rather than forensic in the strictest sense: the patients ate the soup, the soup contained the identified plant, and the plant contained measurable quantities of the toxins expected to cause the observed syndrome. This is a strong circumstantial case, and the authors argue that the combined epidemiological, botanical and plant-analytical findings support the attribution, but they do not claim direct toxicological confirmation. Their transparency on this point offers a practical lesson for incident response teams worldwide: securing biological samples early in a suspected plant poisoning investigation can materially strengthen the evidentiary chain.

What makes this study resonate far beyond the village where the poisoning occurred is the light it sheds on a recurring global hazard. Datura species grow across temperate and tropical regions of the world, and cases of mistaken foraging appear regularly in the medical literature, often involving young children or foragers unfamiliar with the plant’s seedling stage. The fact that a whole family was exposed through a single meal, with outcomes ranging from full recovery to death depending on the dose consumed, compresses the entire dose-response relationship of tropane alkaloid toxicity into one tragic event. The detailed alkaloid distribution data published here give poison control centers concrete numbers to work with when assessing the risk posed by different plant parts, rather than relying on qualitative warnings that jimson weed is simply dangerous.

The study’s integration of disciplines is its defining feature. Epidemiology established who was exposed and how; morphological and molecular botany identified the culprit; validated analytical chemistry quantified the poison in the plant; and computational biology sketched the possible molecular sequelae of exposure. Each element alone would be familiar, but their combination in a single real-world fatal poisoning investigation is rare, and it demonstrates a template that other public health authorities could follow when confronting plant-related toxic emergencies. As wild foraging continues to grow in popularity in many countries, and as climate and land-use changes alter where toxic plants appear, investigations of this kind serve as both a warning and a methodological resource. The Guizhou team’s work transforms a family tragedy into a body of evidence, one that should sharpen vigilance among foragers, clinicians and toxicologists alike.

Subject of Research: Fatal familial Datura stramonium poisoning: plant identification, tropane alkaloid quantification and computational neurotoxicity analysis

Article Title: Clinical and toxicological investigation of a fatal familial poisoning incident associated with Datura stramonium: plant identification, tropane alkaloid quantification and exploratory computational analysis

Article References: Wu, A., Yang, S., Qu, Q., Zhou, Q., Zuo, P., Yang, L., Lei, Y., Guo, H., Pan, R., & Zou, L. (2026). Clinical and toxicological investigation of a fatal familial poisoning incident associated with Datura stramonium: plant identification, tropane alkaloid quantification and exploratory computational analysis. BMC Pharmacology and Toxicology. https://doi.org/10.1186/s40360-026-01230-z

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01230-z

Keywords: Datura stramonium, poisoning, tropane alkaloids, atropine, scopolamine, anisodamine, UPLC-MS/MS, network toxicology, molecular docking, neurotoxicity, anticholinergic toxicity, food safety

The review’s authors, Ravi Patel of ThermoFisher Scientific, Dipen Purohit of Navinta LLC, and Krupalkumar Morker of Frontage Laboratories, compiled analytical methods published between 2010 and 2025 for the simultaneous estimation of the two antihypertensive agents in pharmaceutical formulations and biological matrices. Their motivation stems from a growing tension in pharmaceutical quality control: the same laboratories that validate drug safety generate streams of toxic solvent waste, consume large amounts of energy, and expose analysts to hazardous chemicals. As sustainability expectations rise across the industry, the environmental footprint of the analytical methods themselves has come under scrutiny alongside the performance metrics that regulators traditionally demand.

The two drugs at the center of the assessment are clinically complementary. Amlodipine besylate is a long-acting dihydropyridine calcium channel blocker that relaxes blood vessels by inhibiting calcium ion influx into vascular smooth muscle and cardiac cells, reducing peripheral resistance and the heart’s oxygen demand. Indapamide, a thiazide-like diuretic, works differently: it blocks sodium reabsorption in the kidney’s distal convoluted tubule, increasing sodium and water excretion and lowering plasma volume, while also exerting vasodilatory effects independent of its diuretic action. Combined in a single pill, the two agents achieve better blood pressure control at lower doses than either drug alone, minimizing side effects and improving patient compliance. Hypertension affects approximately 1.28 billion adults worldwide, and according to the World Health Organization nearly 46 percent of those affected are unaware of their condition, making reliable, affordable quality control for these medicines a genuine global health matter.

To quantify environmental performance, the reviewers applied two complementary scoring systems. The first, the Analytical GREEnness metric, or AGREE, was developed at Gdańsk University of Technology and evaluates a method against the twelve principles of green analytical chemistry. It produces a radial, clock-like diagram in which each segment is color-coded from red, indicating poor greenness, to green, indicating strong performance, and yields a cumulative score from 0 to 1. The second tool, the Analytical Eco-Scale, starts from an ideal score of 100 points and deducts penalty points for hazardous reagents, excessive solvent quantities, high energy consumption, waste generation, and safety risks. Methods scoring 75 or above are classified as excellent green analysis, those between 50 and 75 as acceptable, and anything below 50 as ecologically unacceptable.

The results were strikingly consistent. Spectrophotometric methods, which measure how much ultraviolet or visible light a dissolved drug absorbs, achieved AGREE scores between 0.62 and 0.66 and Eco-Scale scores as high as 97. A first derivative ratio spectrophotometry method topped the ranking with an Eco-Scale score of 97, while absorbance ratio, area under the curve, ultraviolet absorbance correction, and Vierordt’s simultaneous equations methods all clustered around AGREE scores of 0.62 to 0.66 with Eco-Scale values of 91. The reasons are straightforward: these techniques require minimal solvent, typically just methanol, need no buffer solutions, involve little or no sample preparation, consume very little energy, and generate almost no waste. For routine quality control of tablets in resource-conscious settings, the review suggests they remain hard to beat.

High-performance thin-layer chromatography, or HPTLC, produced a more nuanced picture that hinged entirely on solvent choice. A stability-indicating HPTLC method using ethanol, ethyl acetate, and triethylamine achieved the single highest AGREE score of the entire comparison, 0.70, along with an Eco-Scale score of 91, demonstrating that planar chromatography can be genuinely green when built on renewable, low-toxicity solvents. By contrast, a conventional HPTLC method relying on dichloromethane, a hazardous chlorinated solvent, scored only 0.50 on AGREE with an Eco-Scale value of 83. The lesson, the authors argue, is that the same instrumental platform can occupy opposite ends of the sustainability spectrum depending on the chemistry chosen to run it.

Conventional reversed-phase high-performance liquid chromatography, the workhorse of pharmaceutical analysis, fared less well. AGREE scores for RP-HPLC methods ranged from 0.47 to 0.61, with Eco-Scale values between 80 and 87. The environmental burden comes from the technique’s fundamental operating model: continuous pumping of mobile phase through a column at flow rates typically between 0.6 and 1.5 milliliters per minute, using organic solvents such as acetonitrile and methanol mixed with phosphate, acetate, or citrate buffers. Every analysis flushes liters of solvent mixture into waste containers over time, and the pumps and detectors draw continuous power. Methods employing phosphate buffers and triethylamine scored at the lower end of the chromatographic range, while stability-indicating variants with optimized solvent compositions achieved slightly better values.

Yet the review also identified a promising path forward within chromatography itself. An RP-HPLC method developed under Analytical Quality by Design, or AQbD, principles, using a mobile phase of methanol and 0.1 percent orthophosphoric acid at pH 4.5, reached an AGREE score of 0.61 and an Eco-Scale score of 87, among the best chromatographic results. AQbD is a systematic framework that identifies the critical method parameters affecting performance and deliberately optimizes them, and the review shows it can be steered toward environmental goals as well as analytical ones. Similarly, an eco-friendly RP-HPLC method for amlodipine impurity profiling that substituted ethanol for more problematic solvents satisfied both greenness metrics while maintaining full separation of the drug’s known impurities, and an optimized UPLC method for amlodipine recorded a low environmental impact value on the HPLC-EAT scale alongside excellent reproducibility.

At the opposite extreme sat the most technologically advanced approach. UPLC–MS/MS and LC–MS/MS methods, which couple ultra-performance liquid chromatography with tandem mass spectrometry, recorded some of the lowest scores in the assessment, with an AGREE value of 0.47 and an Eco-Scale score of 68. These hyphenated techniques are unmatched for sensitivity and specificity, capable of quantifying amlodipine, indapamide, and other antihypertensives in human serum for therapeutic drug monitoring and bioequivalence studies. But that power carries a cost: high-purity solvents, buffer salts, energy-intensive instrumentation, and complex solvent systems all weigh heavily against them on greenness metrics. The review does not suggest abandoning them, since bioanalytical work in plasma and serum has few alternatives, but it does highlight that their routine use where simpler methods suffice carries a substantial and often unexamined environmental price.

The broader message of the review extends well beyond these two drugs. Current ICH validation guidelines focus on precision, accuracy, and robustness but say little about sustainability, and the authors argue that green chemistry principles should be integrated from the earliest stages of method development rather than assessed as an afterthought. Their recommendations include replacing hazardous solvents with greener alternatives such as ethanol and ethyl acetate, minimizing solvent volumes, adopting AQbD frameworks to optimize flow rates and compositions, and pursuing miniaturization and automation. Spectrophotometric and AQbD-assisted HPTLC approaches, they conclude, offer the best combination of green credentials and analytical reliability for routine pharmaceutical quality control. As regulators and the public increasingly expect the pharmaceutical industry to align with sustainable development goals, the environmental scorecard of the laboratory bench, this review suggests, deserves the same rigor as the assay results it produces.

Subject of Research: Greenness assessment of analytical methods for quantifying amlodipine besylate and indapamide

Article Title: Comparative greenness assessment of analytical methods for the estimation of amlodipine besylate and indapamide using green analytical chemistry principles

Article References: Comparative greenness assessment of analytical methods for the estimation of amlodipine besylate and indapamide using green analytical chemistry principles. (n.d.). https://doi.org/10.1007/s44509-026-00013-3

Image Credits: AI Generated

DOI: 10.1007/s44509-026-00013-3

Keywords: green analytical chemistry, amlodipine besylate, indapamide, AGREE metric, Analytical Eco-Scale, spectrophotometry, RP-HPLC, HPTLC, UPLC-MS/MS, Analytical Quality by Design, pharmaceutical analysis, sustainability

The study, published in the journal Immunity, Inflammation and Disease, began with a rigorous chemical inventory of the decoction, which combines Angelicae Sinensis Radix, the root of Angelica sinensis, with Astragali Radix, the root of Astragalus membranaceus, in a precise 1:5 ratio. Using a Vanquish ultra-high-performance liquid chromatograph coupled to a QExactive HFX mass spectrometer, the researchers separated compounds on a Waters HSS T3 column at 40 degrees Celsius with a formic acid-acetonitrile gradient and electrospray ionization in both positive and negative ion modes. The analysis identified 104 compounds, dominated by phenylpropanoids and polyketides, lipids and lipid-like molecules, and organoheterocyclic compounds. This chemical fingerprint became the foundation for everything that followed.

With the compound list in hand, the team turned to network pharmacology, a computational approach that treats a multi-component herbal formula as a network of interacting molecules rather than a single active ingredient. Predicting targets for the identified compounds through SwissTargetPrediction yielded 499 drug-related targets, while searching GeneCards and OMIM for chronic glomerulonephritis produced 2,821 disease targets after redundancy removal. The intersection contained 166 overlapping targets, suggesting a substantial molecular interface between the formula and the disease. Building a protein-protein interaction network in Cytoscape and ranking targets with the CytoHubba MCC algorithm highlighted ten core targets, including B-cell lymphoma-2 (Bcl-2) and Caspase-3, both central players in apoptosis, the genetically programmed form of cell death.

Enrichment analysis through the Metascape platform pointed decisively toward the NF-κB signaling pathway, a master regulator of inflammation. To test whether this computational prediction reflected real biology, the researchers mined two independent gene expression datasets from the Gene Expression Omnibus, GSE116626 with 74 chronic glomerulonephritis samples and GSE104066 with 70 samples. After batch correction and standardization, differential expression analysis identified 414 significantly upregulated genes and 379 downregulated genes, and KEGG pathway analysis showed these genes were also significantly enriched in the NF-κB signaling pathway. The convergence of network pharmacology and patient gene expression data on the same pathway gave the team strong grounds to pursue experimental validation.

Molecular docking provided a structural bridge between chemistry and biology. Five active ingredients with high network centrality, 3-Hexen-1-ol O-β-d-glucopyranoside, 4-hydroxybenzoic acid, caffeic acid, calycosin, and lucidal, were docked against Bcl-2, Caspase-3, and TLR4. All fifteen compound-target pairs showed binding energies below the -5 kcal/mol threshold generally considered indicative of strong binding. Calycosin bound Caspase-3 at -7.2 kcal/mol, while lucidal achieved -8.5 kcal/mol against Caspase-3 and -7.8 kcal/mol against Bcl-2, stabilized by multiple hydrogen bonds with key amino acid residues. These docking scores suggested the herbal compounds could physically engage the apoptotic and inflammatory machinery implicated in the disease.

The first line of experimental evidence came from cell studies using HBZY-1 rat glomerular mesangial cells, whose abnormal behavior is a central driver of chronic glomerulonephritis progression. Rather than applying crude herbal extracts, the team prepared drug-containing serum by administering DBD to rats at three doses, 1.89, 3.78, and 7.56 grams per kilogram, then collecting the resulting serum, an approach that captures only the compounds that actually enter the bloodstream after metabolism. When LPS-stimulated mesangial cells were treated with DBD-containing serum, the abnormally elevated cell viability dropped, secretion of the anti-inflammatory cytokines IL-4 and IL-10 recovered, and Transwell assays showed markedly reduced migration and invasion. Immunofluorescence confirmed that TLR4 and NF-κB protein expression, which LPS had pushed upward, fell significantly after treatment.

The in vivo experiments used a classic adriamycin-induced rat model of chronic glomerulonephritis, established through two tail-vein injections and confirmed by 24-hour urinary protein exceeding 50 milligrams per kilogram. Rats receiving DBD for 30 days showed striking improvements across the board: 24-hour urine protein, serum creatinine, and blood urea nitrogen all fell significantly, while body weight recovered and the kidney index normalized. Pro-inflammatory TNF-α and IL-6 levels declined, and the previously suppressed IL-4 and IL-10 rose. Histological staining with hematoxylin and eosin, Masson, and PAS revealed that the adriamycin-induced damage, including glomerular atrophy, basement membrane thickening, collagen fiber deposition, and inflammatory cell infiltration, was substantially reversed in the treated animals.

The mechanistic heart of the study lies in its analysis of apoptosis and the TLR4/NF-κB axis. In the diseased rats, apoptotic activity was paradoxically suppressed: Cleaved Caspase-3 staining was weak, TUNEL-positive cells were scarce, and mitochondrial membrane potential measured by JC-1 staining indicated inhibited apoptosis. Western blotting showed downregulation of the pro-apoptotic proteins Bax, cytochrome C, Caspase-9, and Caspase-3, alongside upregulation of the anti-apoptotic Bcl-2. DBD treatment reversed this pattern, restoring pro-apoptotic signaling and promoting the controlled cell death needed to clear damaged glomerular cells. Simultaneously, RT-qPCR, Western blotting, immunohistochemistry, and immunofluorescence all demonstrated that DBD downregulated TLR4, MyD88, IκBα, and NF-κB, damping the inflammatory cascade that LPS and adriamycin normally ignite.

This dual action makes biological sense in light of the disease mechanism. When TLR4 on mesangial cell surfaces is activated, it recruits MyD88, promotes IκB phosphorylation and degradation, and triggers NF-κB nuclear translocation, where the transcription factor drives expression of inflammatory cytokines such as TNF-α and IL-1β and of the anti-apoptotic protein Bcl-2. By suppressing this pathway, DBD reduces inflammatory cytokine release; by simultaneously promoting Bax-mediated cytochrome C release and Caspase-9 and Caspase-3 activation, it restores the apoptotic balance whose disruption drives both pathological mesangial accumulation and loss of kidney filtering cells. The authors note that apoptosis is a double-edged sword, but their data indicate that reactivating it in this context slows disease progression rather than accelerating tissue damage.

The findings carry practical significance beyond the laboratory. Current clinical management of chronic glomerulonephritis relies on angiotensin-converting enzyme inhibitors, corticosteroids, and immunosuppressants, all of which carry limitations including variable drug sensitivity, symptom recurrence, and long-term adverse effects such as hyperkalemia, dry cough, increased infection risk, and digestive reactions. A multi-component, multi-target herbal formula that modulates both inflammation and apoptosis could offer a gentler complementary strategy, and the study’s systematic workflow, from chemical profiling through network prediction to animal and cellular validation, provides a template for scientifically grounding other traditional formulas. The researchers conclude that DBD exerts its therapeutic effects on chronic glomerulonephritis by regulating the TLR4/NF-κB signaling pathway, promoting apoptosis, and alleviating inflammation, laying an experimental foundation for explaining its clinical efficacy in modern pharmacological terms.

Subject of Research: Mechanism of action of Danggui Buxue Decoction in treating chronic glomerulonephritis via the TLR4/NF-κB signaling pathway

Article Title: Exploring the Mechanism of Action of Danggui Buxue Decoction in Treating Chronic Glomerulonephritis Based on UPLC‐MS/MS and Network Pharmacology

Article References: Liu, Q., Wang, Y., Wang, X., Yang, H., Pan, Z., & Guo, D. (2026). Exploring the Mechanism of Action of Danggui Buxue Decoction in Treating Chronic Glomerulonephritis Based on UPLC‐MS/MS and Network Pharmacology. Immunity, Inflammation and Disease, 14(9), Article e70497. https://doi.org/10.1002/iid3.70497

Image Credits: AI Generated

DOI: 10.1002/iid3.70497

Keywords: Danggui Buxue Decoction, chronic glomerulonephritis, network pharmacology, UPLC-MS/MS, TLR4/NF-κB pathway, apoptosis, traditional Chinese medicine, kidney disease, HBZY-1 mesangial cells, molecular docking, inflammation, astragalus